OFFICIAL PUBLICATION OF

by its subsidiary APPco

Check Palexia strips: TGA

Megan Haggan 17/02/2020

A labelling problem has seen Seqirus undertake a product defect correction over one batch of Palexia The TGA has advised consumers and health professionals that in consultation with the TGA, the company has undertaken a product defect correction involving a batch of Palexia 100mg sustained-release (SR) tapentadol tablets due to a labelling fault. “Some packages

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Full scope support could halt workforce crisis: review

expansion of scope of practice is the natural trend in contemporary era...

Benjamyn Sung

‘Consumer confusion, pharmacist frustration’ if current system continues

A good start but while we are still governed by a health system that enables each state to legislate their…

Karalyn Huxhagen

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

Check Palexia strips: TGA

Previous Poll: Are patients giving you a hard time?

Next Dispute over pharmacy approval

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Poll: Are patients giving you a hard time?

Next Dispute over pharmacy approval

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.